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Abstract: With notable increases in older adult populations, as well as with the associated cognitive
impairments that can accompany aging, there is significant importance in identifying strategies to
promote cognitive health. The current study explored the implementation of a positive reminiscence
program (REMPOS), a non-pharmacological cognitive therapy that has been previously structured,
defined, and tested in a Spanish sample. We sought to improve the quality of life of institutionalized
older adults with healthy aging, mild cognitive impairment, and Alzheimer’s disease by utilizing
this protocol in these samples. A randomized design with a pre-post measure was conducted over
a three-month period. Two types of interventions were used: the experimental groups received
REMPOS, and the control groups underwent their regular daily institutional programming with
cognitive stimulation techniques. After the intervention, the three experimental groups showed
higher cognitive functioning, decreased depressive symptomatology (except for the MCI group) and
higher evocation of specific positive memories (except for the MCI group). This study supports the
effectiveness of REMPOS and reminiscence therapy, with regard to both cognitive and mood factors
in cognitively impaired older adults.
Keywords: aging; quality of life; cognitive stimulation; memory; reminiscence therapy
1. Introduction
Population aging is exponentially growing and thus we are facing a widespread
phenomenon that affects almost all countries with consequences and implications in all
areas of life and society [1]. This population growth of people over 60 is notable; it is
estimated that by 2050, this growth will double from 11% to 22% [2]. The World Health
Organization (WHO) foresees that life expectancy will exceed 90 years by 2030 in some
developed countries [3].
There is known deterioration of functions that is associated with degenerative disor-
ders in aging, with consequences for the health and functionality of the elderly [4]. For
example, the dementia (or changes in cognition that disrupt functional abilities) prevalence
increases exponentially between 65 and 85 years [5]. In 2012, the World Health Organiza-
tion (WHO) declared dementia as a priority for global public health [6]. While aging is not
the cause of dementia, it is one of its greatest risk factors. In a person suffering from de-
mentia, the three areas generally affected are: cognitive, functional, and behavioral, which
are closely linked to each other. A careful observation of a person affected by dementia is
a great help in identifying what they can and cannot do, and from there, it is possible to
develop an intervention program tailored to their needs [7].
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Alzheimer’s disease (AD), the most common cause of dementia, affects more than
25 million people worldwide, which incurs a significant costs at the social and health
levels [8]. Therefore, it is considered necessary to have an action plan that addresses this
pathology in a multidisciplinary way in terms of the form of action and the professionals
involved.
Pharmacological therapies (PT) are widely used interventions to combat the pro-
gression of AD. However, they have limited effectiveness and they risk adverse side
effects, presenting a need to consider a wider range of intervention options, such as non-
pharmacological therapies (NPT) [9]. NPTs are defined as non-chemical interventions,
theoretically supported, focused and replicable, performed with the patient or the caregiver,
that are capable of obtaining relevant benefits such as subjective well-being [10]. The utility
of applying NPT in healthy aging and dementias is appealing as it presents without side
effects, its implementation is more economical, and it can improve cognition and affect,
enhance independence, and increase the quality of life of older adults [11].
One form of NPT is reminiscence therapy (RT). RT is a therapy with elements in
common with cognitive stimulation intervention and involves recalling and discussing
past activities, events, and experiences, usually using photographs, objects, or music [12].
There are two formats for applying RT: simple reminiscence and life review [12]. Simple
reminiscence involves having conversations to stimulating autobiographical memories
about various topics from the past, such as holidays, clothes, foods, means of transportation,
media, actors, and TV hosts, striking personalities, jobs, and personal experiences. It is
an unstructured and spontaneous process that focuses on positive memories, and can be
applied in an individual or group format. Life review is more structured and individualized,
where the therapist usually guides the individual through significant experiences of their
personal lives and trying to make sense of their past experiences. RT is a guided and
evaluative process that involves an examination of the patient’s life [13,14].
Various sources support the use of reminiscent narratives (reminiscences of past
memories) because they are positive developmental activities that can be individualized
and used as a method of cognitive stimulation in older adults, especially when they
focus on positive past memories [15,16]. Interventions using reminiscence therapy have
become one of the non-pharmacological treatments that has offered proven results of its
effectiveness in older adults [8,12,16–21]. However, in most studies, the effects of RT for
people living with neurocognitive disorders has been shown to have a small positive
effect on cognitive function [9,12,22,23]. Regarding specific cognitive domains, there
is evidence of improvements in both episodic autobiographical memory and personal
semantic memory [9,18,20,21,24]. While much of the literature points to the positive effect
of RT on depressive symptoms [9,22,23], other recent studies have found no significant
differences [20,21].
The effects of RT on quality of life are inconsistent. Some systematic reviews showing
little or no effect [9,12], while others indicate a small or medium effect size on quality of
life [23]. In a recent multicenter randomized controlled trial, significant differences were
found on quality of life with a small and medium effect size [20,21].
In a previous study, an intervention applying positive reminiscence (REMPOS) ther-
apy [25] in older adults with mild cognitive impairment (MCI) sought to promote the
improvement of different psychological processes related to optimal aging [26]. There was
a significant increase in cognitive functioning, life satisfaction, self-esteem, and a decrease
in depressive symptoms in the experimental group compared to the control group [26].
This supports the effective of REMPOS therapy in a cognitively impaired population.
In the present study, we expand upon the previous study in order to test the effective-
ness of the REMPOS program [25] among various cognitive groups. Specifically, the current
study compared the intervention across three types of cognitive groups: healthy aging
[HA], MCI, and AD to explore its effectiveness on the factors of cognition, affective/mood
functioning, and subjective functioning. With relatively limited literature around the ef-
fectiveness of REMPOS, the current study adds to the dearth of literature by exploring
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the effectiveness of this program in a Spanish-speaking population and by exploring its
effectiveness in participants with multiple levels of cognitive functioning.
2. Method
2.1. Participants
The selection of subjects was made in relation to the previously defined sample
inclusion criteria: people over 65 years of age, with healthy aging (HA), MCI, and a
previous diagnosis of AD who either lived in the residence of, or regularly visited, the day
center where the intervention was conducted.
Participants were administered REMPOS intervention (experimental group) or a
conventional cognitive stimulation program (control group). We sought to demonstrate
cognitive (measured with the Mini Cognitive Examination [MEC] and Montreal Cognitive
Assessment [MoCA] instruments), emotional (through the use of the Life Satisfaction Index-
Adults [LSI-A] and Geriatric Depression Scale-30 [GDS-30] instruments), and subjective
(with the use of the Autobiographical Memory Test [AMT] instruments) changes in our
sample through the use of positive reminiscence therapy (REMPOS) through a repeated
measures design in the Spanish population. Specifically, we expected significant cognitive
improvements in the experimental groups of HA, MCI, and AD, as well as significantly
improved emotional variables (depression and life satisfaction) in the experimental groups
for HA, MCI, and AD.
2.2. Instruments
The instruments used both in the pre-treatment phase (first evaluation), and in the
post-treatment phase (second evaluation) were the MoCA [27–29], the MEC [30], the GDS-
30 [31–33], the LSI-A [1,34] and the AMT [35], specific memories for positive stimuli (EPOS),
and for negative stimuli (ENEG).
2.3. Process
There were six phases within this study. Phase 1 was contact with the institutions.
We initially met with the institutions interested in participating in the study, to which
we explained the purpose of this study, the planned timing, as well as the methodology
to be developed for achievement and development. Once this first contact was made,
approximately two or three months before the start of the intervention, the centers agreed
to participate in the study.
Phase 2 was the selection of the participants. The sample was selected by screening
mass or population (mass screening) incidentally through contact with the day centers
and/or residences that agreed to participate in this project. All facilities were located in the
city of Salamanca, Spain. The three participating facilities included AFA (Association of
Relatives of Alzheimer’s Patients), Residencia Madre de la Veracruz, and Residencia las
Mercedarias de la Caridad (in which there was a previous collaboration agreement with
the Pontifical University of Salamanca).
Phase 3 was the pre-test and group formation. Each participant was assigned a
booklet with the tasks for each session (see next section for the description of the program),
furthermore, each task was explained individually and orally.
2.4. Description of the Treatment and Control Groups (AD, HA and MCI)
The total sample was divided into six groups: experimental group with three levels
(HA, MCI and AD) and the control group with three similar levels (HA, MCI and AD).
A total of 77 participants were included, 26 with AD, 24 with MCI and 27 with HA (see
Table 1 for details).
Group selection followed predefined criteria. Participants with a previous AD diagno-
sis became part of that group, all participants in this group participated at a day center. For
participants without a previous AD diagnosis or any associated pathology, MEC scores
were used to classify them into two possible groups: healthy aging (HA, MEC ≥ 25), and
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MCI (MEC < 25), in the absence of a specific neuropsychological battery to diagnose MCI
or AD in early stages [36]. All participants in the last two groups lived in the residences.
Phase 4 was intervention. Once the pre-test had been carried out, the data obtained
were analyzed to form two groups at random. Each group participated in 12 sessions
(experimental groups received positive reminiscence (REMPOS) (HA, MCI and AD), while
the control groups (HA, MCI and AD) participated in regularly scheduled cognitive stimu-
lation activities through their institutions (detailed in Table 2) occurring simultaneously.
The interventions took place twice weekly for one-hour sessions over two months (May–
June). In the control groups, attention, perception, memory, language, inhibition, planning,
reasoning, calculation, and drawing were the primary focus. In the experimental groups,
attention, perception, memory, language, inhibition, planning, reasoning, calculation, draw-
ing, and group dynamics were covered in order to enhance social skills and the expression
of positive feelings, as well as to improve the interrelation of the participants.
Table 1. Group formation.
Groups AD MCI HA Total
Control 6 13 13 32
Experimental 20 11 14 45
Total 26 24 27 77
Abbreviations: AD = Alzheimer’s disease; MCI = Mild cognitive impairment; HA = Healthy aging.
Table 2. Themes of interventions.
Session Positive Reminiscence Cognitive Stimulation
1 Introduction to reminiscence Keys to optimize registration: concentration
2 Things of everyday life Organization of information
3 I present-past-future Display and erroneous attributions
4 Relationships Importance of language
5 Important dates Routes and semantic knowledge
6 Popular parties Understanding of texts and procedural knowledge
7 Work and labor Calculation and arithmetic
8 Games Calculation capacity development
9 Remembering loved ones Relational memory training I
10 Music and memories Relational memory training II
11 Reirpos (positive emotionsthrough laughter) Importance of care and self-regulation
12 Laugh more live more Breathe
The guide used for the cognitive stimulation component was developed by the Pontif-
ical University of Salamanca, from which a large part of the exercises that make up this
part of the intervention were selected [37]. REMPOS was created by one of the authors of
this paper and the protocol is specified in detail elsewhere [25]. Table 2 provides topics of
the sessions for both interventions.
Phase 5. Upon completion of the intervention, as assessment of both groups (exper-
imental and controls) was conducted, using the tests specified in phase three (pre-test




Three-factor repeated measures analysis of variance (ANOVA) were run for each
dependent variable, each one with the following factors: “time” (pre or post, within
subjects), “type of intervention” (experimental or control, between subjects), and “type of
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aging” (HA, MCI, or AD, between subjects). Results values were considered statistically
significant when p < 0.05. Statistical analyses were performed using R 4.0.2 [38], rstatix [39],
ggplot2 [40], WRS2 [41] and Measure of the Effect (MOTE) [42] packages. When double
or triple interactions were significant in the ANOVA, post-hoc analyses were calculated
to test the pre-post differences for each type of aging and type of intervention, adjusting
p-values for multiple comparisons using the Holm correction.
Assumptions checks were run for non-normality using the Shapiro–Wilk test and for
the presence of extreme outliers using interquartile ranges. For the MoCA and GDS-30
scores, there were no extreme outliers, and none of the subgroups showed a significant
deviance from normality. For MEC scores there were no extreme outliers, and only one out
of 12 subgroups (pre-intervention scores for the experimental Alzheimer’s group) showed
deviance from normality (p = 0.007). MoCA, MEC and GDS-30 scores were analyzed with
parametric tests.
The LSI-A, EPOS, and ENEG scores were analyzed with robust and non-parametric
tests. For the LSI-A scores, two extreme outliers were identified in the Alzheimer group,
with a significant deviance from normality for the pre-intervention scores (p = 0.04) of
that same group. For the EPOS scores, one extreme outlier was identified in the post-
intervention scores of the control Alzheimer group, and three subgroups deviated from
normality: post-intervention scores of the control Alzheimer’s group, and both post-
intervention scores of the healthy aging groups (p = 0.0002, p = 0.02, and p = 0.0008). The
ENEG scores showed at least five extreme outliers, mostly from the pre-intervention scores
of the experimental healthy group, and three of the subgroups of the healthy participants
deviated from normality (all ps < 0.01). Robust ANOVA (based on Wilcox WRS functions)
was used for the analyses of the LSI-A, EPOS and ENEG scores, in these cases post-hoc
analyses were performed using Wilcoxon paired sample tests.
A total of 77 subjects (58 women) were part of the centers mentioned in the previous
section, and residents in the city of Salamanca (Spain). The average age was 83.1 years
(mean age men = 79.3 years; women = 84.3 years). Regarding education, 5% had no formal
education, 60% had only primary education, 20% finished high school, and 15% completed
university. For the main descriptive results of the types of intervention (experimental or
control), types of aging (AD, MCI, or HA), and time (pre- or post-intervention), see Table 3.
Results for the MoCA scores showed a significant three-way interaction (F(2,71) = 4.88,
p = 0.01, η2G = 0.03, 95% CI [0.00, 0.12]) between type of intervention, type of aging,
and time. For the AD group, there was a large and significant effect of intervention for
experimental group (t(19) = 10.3, p < 0.001, Hedges’ g = 2.2, 95% CI [0.46, 3.47]), but not for
the control group (t(5) = 0.39, p = 0.71, Hedges’ g = 0.13, 95% CI [−0.8, 1]). For the MCI
group, there was a significant effect in both the experimental (t(10) = 2.5, p = 0.03, Hedges’
g = 0.70, 95% CI [0.03, 1.23]) and the control groups (t(12) = 3.75, p = 0.003, Hedges’ g = 0.97,
95% CI [0.35, 1.47]). In the healthy aging group, there was a significant effect in both the
experimental (t(13) = 3.06, p = 0.009, Hedges’ g = 0.77, 95% CI [0.23, 1.23]), and the control
groups (t(12) = 4.49, p < 0.001, Hedges’ g = 1.16, 95% CI [0.50, 1.58]). The triple interaction
was mostly driven by the fact that both the experimental and control groups in the MCI
and HA groups showed similar improvement after intervention, but on the other hand,
the experimental AD participants had even higher improvement scores, while the control
group showed improvement after intervention (see Figure 1).
Results for the MEC scores also showed a significant three-way interaction (F(2,71) = 3.33,
p = 0.04, η2G = 0.02, 95% CI [0.00, 0.11]) between type of intervention, type of aging and
time. For the Alzheimer’s group, there was a large and significant effect of intervention
for the experimental group (t(19) = 4.65, p < 0.001, Hedges’ g = 1.0, 95% CI [0.35, 1.50]),
and there was also a large and significant effect of time in the control group, but in the
opposite direction (t(5) = −2.58, p = 0.049, Hedges’ g = 0.89, 95% CI [−0.97, 2.37]), while
participants in the experimental group improved their scores after intervention, those
in the control group had lower scores on their second assessment. For the MCI group,
there was a significant effect in the experimental group (t(10) = 3.73, p = 0.004, Hedges’
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g = 1.04, 95% CI [−0.02, 1.84]), but not in the control group (t(12) = 2.0, p = 0.069, Hedges’
g = 0.52, 95% CI [−0.22, 1.10]). In the healthy aging group, there was also a significant
effect in the experimental group (t(13) = 3.61, p = 0.003, Hedges’ g = 0.91, 95% CI [0.04,
1.44]), but not in the control group (t(12) = 1.72, p = 0.11, Hedges’ g = 0.45, 95% CI [−0.30,
1.05]). Considering the MEC scores, participants in all three cognitive experimental groups
showed improvements after intervention. In this case, the triple interaction was driven by
the fact that participants with AD in the control group showed significantly lower scores
on the second assessment (see Figure 1).
Table 3. Descriptive statistics for the six main cognitive variables assessed before and after interven-
tion (control or experimental groups) for the three types of aging groups. Means (SD).
Control Experimental
Pre Post Pre Post
AD group n = 6 n = 20
MoCA 19.2 (5.23) 19.7 (2.58) 11.7 (3.21) 17.2 (3.32)
MEC 28 (1.90) 26 (2.45) 20.4 (3.22) 23.9 (2.77)
GDS-30 7.67 (2.16) 7.83 (4.62) 9.2 (4.20) 7.8 (4.03)
LSI-A 27 (6.51) 25 (7.69) 24.6 (5.46) 27.0 (5.84)
AMT-EPOS 2.17 (0.75) 2.17 (0.41) 1.9 (0.97) 3.5 (0.89)
AMT-ENEG 2.5 (1.23) 2.17 (0.75) 2.15 (1.09) 2.8 (0.89)
MCI group n = 13 n = 11
MoCA 11.2 (4.25) 14.8 (3.36) 13.1 (4.59) 15.7 (5.08)
MEC 19.9 (3.45) 21.7 (3.40) 19.6 (3.98) 23.5 (4.53)
GDS-30 13.5 (5.55) 12.6 (6.53) 13.4 (5.57) 12.7 (6.40)
LSI-A 22.6 (6.5) 21.1 (6.75) 20.4 (4.41) 21.7 (6.25)
AMT-EPOS 1.23 (1.17) 1.62 (0.77) 1.36 (1.12) 1.91 (1.14)
AMT-ENEG 2.46 (0.88) 2.38 (1.04) 1.73 (1.42) 2.36 (1.21)
HA group n = 13 n = 14
MoCA 17.6 (3.62) 21.6 (2.53) 20.7 (4.27) 24.4 (3.15)
MEC 26.4 (1.39) 27.2 (2.24) 28.6 (2.53) 30.6 (2.85)
GDS-30 15.1 (4.70) 10.5 (3.53) 11.9 (5.10) 8.07 (3.91)
LSI-A 18.5 (5.88) 21.5 (3.69) 22.4 (5.26) 25.1 (5.01)
AMT-EPOS 1.23 (0.93) 4.31 (0.95) 1.79 (0.80) 4.43 (1.02)
AMT-ENEG 1.62 (1.50) 3.92 (1.60) 2.86 (0.54) 4.21 (0.98)
Abbreviations: AD = Alzheimer’s disease; AMT-EPOS = autobiographical memory test, specific memories for
positive stimuli; AMT-ENEG = autobiographical memory test, specific memories for negative stimuli; MCI =
mild cognitive impairment; HA = healthy aging; MoCA = Montreal cognitive assessment; MEC = mini cognitive
examination; GDS-30 = geriatric depression scale-30; LSI-A = life satisfaction index-adults.
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Figure 1. MoCA and MEC difference scores for three types of aging before and after intervention,
comparing the REMPOS program (experimental group) to standard cognitive stimulation (control
group). Note: Error bars indicate standard errors. Alzheimer = Alzheimer’s disease; MCI = mild
cognitive impairment; MoCA = Montreal cognitive assessment; MEC = mini cognitive examination.
* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, testing a significant difference from zero.
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The MoCA and MEC scores showed a strong correlation between them before (r = 0.734,
df = 75, p < 0.001) and after intervention (r = 0.789, df = 75, p < 0.001). For the AD group, the
MoCA and MEC scores showed the same clear pattern where only the experimental group
benefited from the intervention. The difference found between the MoCA and MEC results
in the MCI and HA groups could be interpreted as a matter of difference in sensitivity,
where the MoCA group could have been more sensitive to cognitive changes.
For the GDS-30 results, there was no significant three-way interaction (F(2,71) = 0.70,
p = 0.50, η2G = 0.002, 95% CI [0.00, 0.03]) between type of intervention, type of aging, and
time. There was only a significant two-way interaction between type of aging and time
(F(2,71) = 8.75, p < 0.001, η2G = 0.03, 95% CI [0.00, 0.13]), but not between type of aging and
type of intervention (F(2,71) = 1.02, p = 0.37, η2G = 0.025, 95% CI [0.00, 0.12]), nor between
type of intervention and time (F(1,71) = 0.05, p = 0.83, η2G < 0.001, 95% CI [0.00, 0.02]).
There were significant main effects of type of aging (F(2,71) = 6.22, p = 0.003, η2G = 0.13,
95% CI [0.01, 0.29]), and time (F(1,71) = 19.95, p < 0.001, η2G = 0.034, 95% CI [0.00, 0.16]),
but not of type of intervention (F(1,71) = 0.38, p = 0.54, η2G = 0.005, 95% CI [0.00, 0.08]). In
the post-hoc analyses, there was a significant effect of intervention both for experimental
(t(13) = 4.78, p < 0.001, Hedges’ g = 1.20, 95% CI [0.41, 1.81]) and the control (t(12) = 4.38,
p < 0.001, Hedges’ g = 1.14, 95% CI [0.26, 1.81]) groups in the healthy aging sample, but
only for the experimental group (t(19) = 3.07, p = 0.006, Hedges’ g = 0.66, 95% CI [0.12,
1.11]) in the Alzheimer sample. The MCI participants showed no significant difference
after intervention in either the experimental (t(10) = 0.36, p = 0.728, Hedges’ g = 0.10, 95%
CI [−0.54, 0.68]) or the control groups (t(12) = 2.01, p = 0.068, Hedges’ g = 0.52, 95% CI
[−0.05, 1.04]). As the results (Figure 2) indicate, the two-way interaction found between
type of aging and time was driven by an improvement in GDS-30 scores after intervention
only in the healthy aging groups, regardless of type of intervention. Healthy participants
in the experimental and control groups showed lower GDS-30 scores after intervention.
For the LSI-A results, the robust two-way ANOVA for the difference scores (post minus
pre) found a significant main effect of type of aging (p = 0.035) and type of intervention
(p = 0.011), but no interaction between those factors (p = 0.083). Post-hoc analyses using
Wilcoxon paired sample tests found no significant difference between the post and pre-
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4. Discussion and Conclusions
This study explored the cognitive (measured with MEC and MoCA), emotional/affective
(measured with LSI-A and GDS-30), and subjective (measured with AMT) functioning
of older adults with (AD, MCI) and without (HA) cognitive impairment after positive
reminiscence therapy (REMPOS).
The current study explored how positive reminiscence therapy (REMPOS) is related
to the well-being of the elderly in the cognitive and affective (mood) variables. There were
notably significant improvements between the pretest and posttest scores in relation to the
intervention (experimental and controls), in the three cognitive groups (AD, MCI and HA)
studied.
While reminiscence was considered as a possible sign of dysfunction and/or deteriora-
tion when it occurred at the end of life, it is currently considered to have adaptive functions,
serving as a positive predictor of mental health in the elderly [18]. An intervention based on
reminiscence therapy was associated with a statistically significant increase in the general
cognitive level, a decrease in depressive symptomatology, an increase in life satisfaction,
and a greater evocation of specific positive and negative memories [26].
The current study presents with some notable limitations. The sample size is small,
namely people with AD in the control group. Our sample groups were defined by a
commonly used cognitive screening tool (MEC) with normal group distributions. However,
in comparison to another cognitive screening tool (MoCA), our group distributions did
not fit typical score cutoffs even when the correlation between those measures was high.
There are several considerations, among which are education, which can have notable
effects on MoCA performance. Specifically, the majority of our sample had education
levels at elementary school or below, which could have had performance effects on this
measure. Among other considerations, all participants in groups defined using MEC
scores lived in geriatric residencies, which could be associated with a higher prevalence in
cognitive decline still undiagnosed or in early stages, or with a context lacking stimulating
activities. Thus, while we feel the groups were appropriately identified, they did not
perform as traditionally as we expected on all cognitive tasks. Nonetheless, all three of our
experimental groups did show improvements in this task.
To highlight some of the positive effects, we underscore the reduced depressive symp-
tomatology in two experimental groups (AD and HA), compared to the control groups
(MCI, AD and HA). The question remains as to why our MCI experimental group did not
respond as strongly to the intervention as the other experimental groups. Possible consid-
erations are the aforementioned group factors such as limited education and atypically
baseline group measurements; that is, it is possible that at least some participants in the
MCI group may have been better characterized as AD. Another possible consideration is
the degree of awareness or agnosia that is specific to the MCI population; this very specific
level of awareness in this group may have affected their confidence in the intervention and
thus affected their outcomes. Notably, there have been some reflections on the variability
of MCI groups in intervention outcomes and how it can affect effectiveness results [43,44].
Our overall results are consistent with the results of various studies that propose
the reduction of depressed moods as one of the main objectives of this type of therapy
in older adults [17,45–47]. Any intervention, particularly non-pharmacological, that can
reduce depressive symptoms to any extent in older adults has clinical importance [48], as
depressive symptoms are quite common in aging. This result is consistent with previous
studies that show that reminiscence plays an important role in the health of the elderly
because of its therapeutic and adaptive nature, and therefore, influences their quality of
life [8,48]. This study allows us to approach the improvement of the quality of life of the
elderly from a non-pharmacological perspective. While reminiscence therapies have been
showing their effectiveness in previous studies, the current study goes a step further by
doing it with older adults of different cognitive abilities.
We can conclude that this work shows that positive results were obtained from the
application of an NPT program in aging. It is important to highlight that individuals with
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cognitive impairment benefit more from it, although its widespread application seems
to be optimal in relation to cognitive and emotional aspects. Overall, the results found
are quite encouraging in order to indicate the need to continue to promote studies on this
topic, as the use of positive reminiscence therapy has demonstrated a significant decrease
in depressive symptomatology, an increase in cognitive level, life satisfaction, and the
evocation of specific memories, all imperative factors in the psychological well-being and
quality of life of the elderly.
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